{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,12]],"date-time":"2026-11-12T23:37:53Z","timestamp":1794526673991,"version":"4.9.1"},"reference-count":64,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,2,6]],"date-time":"2026-02-06T00:00:00Z","timestamp":1770336000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,2,9]],"date-time":"2026-02-09T00:00:00Z","timestamp":1770595200000},"content-version":"vor","delay-in-days":3,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100002347","name":"Bundesministerium f\u00fcr Bildung und Forschung","doi-asserted-by":"publisher","award":["01KD2206A\/SATURN3"],"award-info":[{"award-number":["01KD2206A\/SATURN3"]}],"id":[{"id":"10.13039\/501100002347","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100011102","name":"EC | Seventh Framework Programme","doi-asserted-by":"publisher","award":["602783"],"award-info":[{"award-number":["602783"]}],"id":[{"id":"10.13039\/100011102","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100009591","name":"Ministerium f\u00fcr Innovation, Wissenschaft und Forschung des Landes Nordrhein-Westfalen","doi-asserted-by":"publisher","award":["CANcer TARgeting (CANTAR)"],"award-info":[{"award-number":["CANcer TARgeting (CANTAR)"]}],"id":[{"id":"10.13039\/501100009591","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001659","name":"Deutsche Forschungsgemeinschaft","doi-asserted-by":"publisher","award":["418179183"],"award-info":[{"award-number":["418179183"]}],"id":[{"id":"10.13039\/501100001659","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001659","name":"Deutsche Forschungsgemeinschaft","doi-asserted-by":"publisher","award":["421166016"],"award-info":[{"award-number":["421166016"]}],"id":[{"id":"10.13039\/501100001659","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001659","name":"Deutsche Forschungsgemeinschaft","doi-asserted-by":"publisher","award":["450917483"],"award-info":[{"award-number":["450917483"]}],"id":[{"id":"10.13039\/501100001659","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100005972","name":"Deutsche Krebshilfe","doi-asserted-by":"publisher","award":["70115201"],"award-info":[{"award-number":["70115201"]}],"id":[{"id":"10.13039\/501100005972","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100008658","name":"Deutsches Krebsforschungszentrum","doi-asserted-by":"publisher","award":["DKTK"],"award-info":[{"award-number":["DKTK"]}],"id":[{"id":"10.13039\/100008658","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Deutsches Konsortium f\u00fcr Translationale Krebsforschung"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Nat Commun"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>\n                    GATA6 promotes epithelial phenotypes and limits epithelial-to-mesenchymal (EMT) transition in pancreatic ductal adenocarcinoma (PDAC). Here we show that GATA6 defines a tumor cell state that induces MHCI expression and anti-tumor cytotoxicity upon therapy. In human PDAC, GATA6 expression correlates with immune cell infiltration, and spatial analysis reveals interaction between GATA6\n                    <jats:sup>+<\/jats:sup>\n                    tumor cells and CD8\n                    <jats:sup>+<\/jats:sup>\n                    T cells. In murine PDAC, MEK inhibition (MEKi) enriches antigenicity-related gene sets in GATA6\n                    <jats:sup>high<\/jats:sup>\n                    cells, while GATA6 knockout or degradation impairs MEKi-induced MHCI upregulation. High-GATA6 tumors respond to MEKi with increased MHCI, enhancing T-cell cytotoxicity, whereas GATA6 loss abolishes this effect. Treatment-induced EMT reduces GATA6\n                    <jats:sup>+<\/jats:sup>\n                    populations and MHCI expression, which is restored by combining MEKi with HDAC inhibitors, enhancing GATA6\n                    <jats:sup>+<\/jats:sup>\n                    tumor cells, MHCI, CD8\n                    <jats:sup>+<\/jats:sup>\n                    T cell infiltration, tumor suppression, and survival. These findings suggest that therapeutic strategies promoting a GATA6-driven tumor cell state improve immune recognition of PDAC cells and potentiate anti-tumor cytotoxic effects.\n                  <\/jats:p>","DOI":"10.1038\/s41467-026-69013-y","type":"journal-article","created":{"date-parts":[[2026,2,6]],"date-time":"2026-02-06T17:06:03Z","timestamp":1770397563000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":4,"title":["Combined targeted and epigenetic-based therapy enhances antitumor immunity by stabilizing GATA6-dependent MHCI expression in pancreatic ductal adenocarcinoma"],"prefix":"10.1038","volume":"17","author":[{"given":"JuanFei","family":"Peng","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"JiaJin","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9681-4890","authenticated-orcid":false,"given":"Georgia","family":"Antonopoulou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rui","family":"Fang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9064-0356","authenticated-orcid":false,"given":"Bikash","family":"Adhikari","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4525-2901","authenticated-orcid":false,"given":"Markus","family":"Vogt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5299-6335","authenticated-orcid":false,"given":"Elmar","family":"Wolf","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9008-2158","authenticated-orcid":false,"given":"Chong","family":"Sun","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shangce","family":"Du","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laura","family":"Godfrey","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aayush","family":"Gupta","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marija","family":"Trajkovic-Arsic","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicole","family":"Teichmann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Barbara T.","family":"Gr\u00fcnwald","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Niklas","family":"Krebs","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7269-5433","authenticated-orcid":false,"given":"Katja","family":"Steiger","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3400-7254","authenticated-orcid":false,"given":"Carolin","family":"Mogler","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kristina","family":"Althoff","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xin","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0009-0349-3756","authenticated-orcid":false,"given":"Giovanni","family":"Giglio","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sven-Thorsten","family":"Liffers","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Konstantinos","family":"Savvatakis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6039-6957","authenticated-orcid":false,"given":"Rickmer","family":"Braren","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3160-0634","authenticated-orcid":false,"given":"Rita T.","family":"Lawlor","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1678-739X","authenticated-orcid":false,"given":"Aldo","family":"Scarpa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Diana","family":"Behrens","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Karl S.","family":"Lang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0075-5679","authenticated-orcid":false,"given":"Phyllis F.","family":"Cheung","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8772-4778","authenticated-orcid":false,"given":"Jens T.","family":"Siveke","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,2,6]]},"reference":[{"key":"69013_CR1","doi-asserted-by":"publisher","first-page":"1665","DOI":"10.1136\/gutjnl-2015-311256","volume":"66","author":"P Martinelli","year":"2017","unstructured":"Martinelli, P. et al. GATA6 regulates EMT and tumour dissemination, and is a marker of response to adjuvant chemotherapy in pancreatic cancer. Gut 66, 1665\u20131676 (2017).","journal-title":"Gut"},{"key":"69013_CR2","doi-asserted-by":"publisher","first-page":"535","DOI":"10.1136\/gutjnl-2021-325803","volume":"72","author":"MP de Andr\u00e9s","year":"2023","unstructured":"de Andr\u00e9s, M. P. et al. GATA4 and GATA6 loss-of-expression is associated with extinction of the classical programme and poor outcome in pancreatic ductal adenocarcinoma. Gut 72, 535\u2013548 (2023).","journal-title":"Gut"},{"key":"69013_CR3","doi-asserted-by":"publisher","first-page":"4901","DOI":"10.1158\/1078-0432.CCR-19-3724","volume":"26","author":"GM O\u2019Kane","year":"2020","unstructured":"O\u2019Kane, G. M. et al. GATA6 expression distinguishes classical and basal-like subtypes in advanced pancreatic cancer. Clin. Cancer Res. 26, 4901\u20134910 (2020).","journal-title":"Clin. Cancer Res."},{"key":"69013_CR4","doi-asserted-by":"publisher","first-page":"1344","DOI":"10.1158\/1078-0432.CCR-17-2994","volume":"24","author":"KL Aung","year":"2018","unstructured":"Aung, K. L. et al. Genomics-driven precision medicine for advanced pancreatic cancer: early results from the COMPASS trial. Clin. Cancer Res. 24, 1344\u20131354 (2018).","journal-title":"Clin. Cancer Res."},{"key":"69013_CR5","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-021-25728-8","volume":"12","author":"J Bragelmann","year":"2021","unstructured":"Bragelmann, J. et al. MAPK-pathway inhibition mediates inflammatory reprogramming and sensitizes tumors to targeted activation of innate immunity sensor RIG-I. Nat. Commun. 12, 5505 (2021).","journal-title":"Nat. Commun."},{"key":"69013_CR6","doi-asserted-by":"publisher","first-page":"252","DOI":"10.3390\/biomedicines11020252","volume":"11","author":"V Heredia-Soto","year":"2023","unstructured":"Heredia-Soto, V. et al. The relationship between the expression of GATA4 and GATA6 with the clinical characteristics and prognosis of resectable pancreatic adenocarcinoma. Biomedicines 11, 252 (2023).","journal-title":"Biomedicines"},{"key":"69013_CR7","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-021-94544-3","volume":"11","author":"K Duan","year":"2021","unstructured":"Duan, K. et al. The value of GATA6 immunohistochemistry and computer-assisted diagnosis to predict clinical outcome in advanced pancreatic cancer. Sci. Rep. 11, 14951 (2021).","journal-title":"Sci. Rep."},{"key":"69013_CR8","doi-asserted-by":"publisher","first-page":"231","DOI":"10.1038\/s41588-019-0566-9","volume":"52","author":"M Chan-Seng-Yue","year":"2020","unstructured":"Chan-Seng-Yue, M. et al. Transcription phenotypes of pancreatic cancer are driven by genomic events during tumor evolution. Nat. Genet. 52, 231\u2013240 (2020).","journal-title":"Nat. Genet."},{"key":"69013_CR9","doi-asserted-by":"publisher","first-page":"441","DOI":"10.1158\/0008-5472.CAN-22-3050","volume":"83","author":"HL Williams","year":"2023","unstructured":"Williams, H. L. et al. Spatially resolved single-cell assessment of pancreatic cancer expression subtypes reveals co-expressor phenotypes and extensive intratumoral heterogeneity. Cancer Res. 83, 441\u2013455 (2023).","journal-title":"Cancer Res."},{"key":"69013_CR10","doi-asserted-by":"publisher","first-page":"150","DOI":"10.1158\/1078-0432.CCR-20-2831","volume":"27","author":"JT Topham","year":"2021","unstructured":"Topham, J. T. et al. Subtype-discordant pancreatic ductal adenocarcinoma tumors show intermediate clinical and molecular characteristics. Clin. Cancer Res. 27, 150\u2013157 (2021).","journal-title":"Clin. Cancer Res."},{"key":"69013_CR11","doi-asserted-by":"publisher","first-page":"1362","DOI":"10.1038\/s43018-023-00628-6","volume":"4","author":"X Zhou","year":"2023","unstructured":"Zhou, X. et al. Persister cell phenotypes contribute to poor patient outcomes after neoadjuvant chemotherapy in PDAC. Nat. Cancer 4, 1362\u20131381 (2023).","journal-title":"Nat. Cancer"},{"key":"69013_CR12","doi-asserted-by":"publisher","first-page":"766","DOI":"10.1136\/gutjnl-2020-321397","volume":"71","author":"B Kloesch","year":"2022","unstructured":"Kloesch, B. et al. A GATA6-centred gene regulatory network involving HNFs and DeltaNp63 controls plasticity and immune escape in pancreatic cancer. Gut 71, 766\u2013777 (2022).","journal-title":"Gut"},{"key":"69013_CR13","doi-asserted-by":"publisher","first-page":"6119","DOI":"10.1016\/j.cell.2021.11.017","volume":"184","author":"S Raghavan","year":"2021","unstructured":"Raghavan, S. et al. Microenvironment drives cell state, plasticity, and drug response in pancreatic cancer. Cell 184, 6119\u20136137.e6126 (2021).","journal-title":"Cell"},{"key":"69013_CR14","doi-asserted-by":"publisher","first-page":"e002899","DOI":"10.1136\/jitc-2021-002899","volume":"9","author":"A Hazini","year":"2021","unstructured":"Hazini, A., Fisher, K. & Seymour, L. Deregulation of HLA-I in cancer and its central importance for immunotherapy. J. Immunother. Cancer 9, e002899 (2021).","journal-title":"J. Immunother. Cancer"},{"key":"69013_CR15","doi-asserted-by":"publisher","first-page":"100","DOI":"10.1038\/s41586-020-2229-5","volume":"581","author":"K Yamamoto","year":"2020","unstructured":"Yamamoto, K. et al. Autophagy promotes immune evasion of pancreatic cancer by degrading MHC-I. Nature 581, 100\u2013105 (2020).","journal-title":"Nature"},{"key":"69013_CR16","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-020-15979-2","volume":"11","author":"D Baumann","year":"2020","unstructured":"Baumann, D. et al. Proimmunogenic impact of MEK inhibition synergizes with agonist anti-CD40 immunostimulatory antibodies in tumor therapy. Nat. Commun. 11, 2176 (2020).","journal-title":"Nat. Commun."},{"key":"69013_CR17","doi-asserted-by":"publisher","first-page":"609","DOI":"10.1016\/j.immuni.2016.01.024","volume":"44","author":"PJR Ebert","year":"2016","unstructured":"Ebert, P. J. R. et al. MAP Kinase Inhibition Promotes T Cell and Anti-tumor Activity in Combination with PD-L1 Checkpoint Blockade. Immunity 44, 609\u2013621 (2016).","journal-title":"Immunity"},{"key":"69013_CR18","doi-asserted-by":"publisher","first-page":"279ra241","DOI":"10.1126\/scitranslmed.aaa4691","volume":"7","author":"S Hu-Lieskovan","year":"2015","unstructured":"Hu-Lieskovan, S. et al. Improved antitumor activity of immunotherapy with BRAF and MEK inhibitors in BRAF(V600E) melanoma. Sci. Transl. Med. 7, 279ra241 (2015).","journal-title":"Sci. Transl. Med."},{"key":"69013_CR19","doi-asserted-by":"publisher","first-page":"954","DOI":"10.18632\/oncotarget.652","volume":"3","author":"JA McCubrey","year":"2012","unstructured":"McCubrey, J. A. et al. Mutations and deregulation of Ras\/Raf\/MEK\/ERK and PI3K\/PTEN\/Akt\/mTOR cascades which alter therapy response. Oncotarget 3, 954\u2013987 (2012).","journal-title":"Oncotarget"},{"key":"69013_CR20","doi-asserted-by":"publisher","first-page":"779","DOI":"10.1158\/1541-7786.MCR-06-0077","volume":"4","author":"M Kono","year":"2006","unstructured":"Kono, M. et al. Role of the mitogen-activated protein kinase signaling pathway in the regulation of human melanocytic antigen expression. Mol. Cancer Res. 4, 779\u2013792 (2006).","journal-title":"Mol. Cancer Res."},{"key":"69013_CR21","doi-asserted-by":"publisher","first-page":"516","DOI":"10.1001\/jamaoncol.2016.5383","volume":"3","author":"V Chung","year":"2017","unstructured":"Chung, V. et al. Effect of selumetinib and MK-2206 vs oxaliplatin and fluorouracil in patients with metastatic pancreatic cancer after prior therapy: SWOG S1115 study randomized clinical trial. JAMA Oncol. 3, 516\u2013522 (2017).","journal-title":"JAMA Oncol."},{"key":"69013_CR22","doi-asserted-by":"publisher","first-page":"97","DOI":"10.1007\/s11523-016-0469-y","volume":"12","author":"JL Van Laethem","year":"2017","unstructured":"Van Laethem, J. L. et al. Phase I\/II study of refametinib (BAY 86-9766) in combination with gemcitabine in advanced pancreatic cancer. Target Oncol. 12, 97\u2013109 (2017).","journal-title":"Target Oncol."},{"key":"69013_CR23","doi-asserted-by":"publisher","first-page":"26835","DOI":"10.1073\/pnas.1914915116","volume":"116","author":"RL Porter","year":"2019","unstructured":"Porter, R. L. et al. Epithelial to mesenchymal plasticity and differential response to therapies in pancreatic ductal adenocarcinoma. Proc. Natl. Acad. Sci. USA 116, 26835\u201326845 (2019).","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"69013_CR24","doi-asserted-by":"publisher","first-page":"567","DOI":"10.1016\/j.ccell.2020.08.015","volume":"38","author":"L Gabitova-Cornell","year":"2020","unstructured":"Gabitova-Cornell, L. et al. Cholesterol pathway inhibition induces TGF-beta signaling to promote basal differentiation in pancreatic cancer. Cancer Cell 38, 567\u2013583.e11 (2020).","journal-title":"Cancer Cell"},{"key":"69013_CR25","doi-asserted-by":"publisher","first-page":"6334","DOI":"10.1093\/nar\/gkx212","volume":"45","author":"VK Mishra","year":"2017","unstructured":"Mishra, V. K. et al. Histone deacetylase class-I inhibition promotes epithelial gene expression in pancreatic cancer cells in a BRD4-and MYC-dependent manner. Nucleic Acids Res. 45, 6334\u20136349 (2017).","journal-title":"Nucleic Acids Res."},{"key":"69013_CR26","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-023-42178-6","volume":"14","author":"G Liang","year":"2023","unstructured":"Liang, G. et al. Inhibiting stromal Class I HDACs curbs pancreatic cancer progression. Nat. Commun. 14, 7791 (2023).","journal-title":"Nat. Commun."},{"key":"69013_CR27","doi-asserted-by":"publisher","first-page":"294","DOI":"10.1186\/s40425-019-0745-3","volume":"7","author":"AC Bretz","year":"2019","unstructured":"Bretz, A. C. et al. Domatinostat favors the immunotherapy response by modulating the tumor immune microenvironment (TIME). J. Immunother. Cancer 7, 294 (2019).","journal-title":"J. Immunother. Cancer"},{"key":"69013_CR28","doi-asserted-by":"publisher","first-page":"9601","DOI":"10.1158\/0008-5472.CAN-07-5270","volume":"68","author":"AF Setiadi","year":"2008","unstructured":"Setiadi, A. F. et al. Epigenetic enhancement of antigen processing and presentation promotes immune recognition of tumors. Cancer Res. 68, 9601\u20139607 (2008).","journal-title":"Cancer Res."},{"key":"69013_CR29","doi-asserted-by":"publisher","first-page":"5577","DOI":"10.1016\/j.cell.2021.09.022","volume":"184","author":"BT Grunwald","year":"2021","unstructured":"Grunwald, B. T. et al. Spatially confined sub-tumor microenvironments in pancreatic cancer. Cell 184, 5577\u20135592. e5518 (2021).","journal-title":"Cell"},{"key":"69013_CR30","doi-asserted-by":"publisher","first-page":"1034","DOI":"10.1136\/gutjnl-2018-317706","volume":"68","author":"C Maurer","year":"2019","unstructured":"Maurer, C. et al. Experimental microdissection enables functional harmonisation of pancreatic cancer subtypes. Gut 68, 1034\u20131043 (2019).","journal-title":"Gut"},{"key":"69013_CR31","doi-asserted-by":"publisher","first-page":"1378","DOI":"10.1016\/j.immuni.2024.04.021","volume":"57","author":"F De Sanctis","year":"2024","unstructured":"De Sanctis, F. et al. Expression of the membrane tetraspanin claudin 18 on cancer cells promotes T lymphocyte infiltration and antitumor immunity in pancreatic cancer. Immunity 57, 1378\u20131393.e1314 (2024).","journal-title":"Immunity"},{"key":"69013_CR32","doi-asserted-by":"publisher","first-page":"2030","DOI":"10.1136\/gutjnl-2020-322874","volume":"71","author":"S Martens","year":"2022","unstructured":"Martens, S. et al. Discovery and 3D imaging of a novel \u0394Np63-expressing basal cell type in human pancreatic ducts with implications in disease. Gut 71, 2030\u20132042 (2022).","journal-title":"Gut"},{"key":"69013_CR33","doi-asserted-by":"publisher","first-page":"1825","DOI":"10.1038\/cdd.2014.96","volume":"21","author":"P Duewell","year":"2014","unstructured":"Duewell, P. et al. RIG-I-like helicases induce immunogenic cell death of pancreatic cancer cells and sensitize tumors toward killing by CD8(+) T cells. Cell Death Differ. 21, 1825\u20131837 (2014).","journal-title":"Cell Death Differ."},{"key":"69013_CR34","doi-asserted-by":"publisher","first-page":"178","DOI":"10.1016\/j.immuni.2018.06.006","volume":"49","author":"J Li","year":"2018","unstructured":"Li, J. et al. Tumor cell-intrinsic factors underlie heterogeneity of immune cell infiltration and response to immunotherapy. Immunity 49, 178\u2013193.e177 (2018).","journal-title":"Immunity"},{"key":"69013_CR35","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1186\/s13148-024-01623-z","volume":"16","author":"LK Godfrey","year":"2024","unstructured":"Godfrey, L. K. et al. Pancreatic cancer acquires resistance to MAPK pathway inhibition by clonal expansion and adaptive DNA hypermethylation. Clin. Epigenetics 16, 13 (2024).","journal-title":"Clin. Epigenetics"},{"key":"69013_CR36","doi-asserted-by":"publisher","first-page":"239","DOI":"10.1080\/08830180902978120","volume":"28","author":"F Zhou","year":"2009","unstructured":"Zhou, F. Molecular mechanisms of IFN-\u03b3 to up-regulate MHC class I antigen processing and presentation. Int. Rev. Immunol. 28, 239\u2013260 (2009).","journal-title":"Int. Rev. Immunol."},{"key":"69013_CR37","doi-asserted-by":"publisher","first-page":"4093","DOI":"10.1158\/1538-7445.AM2018-4093","volume":"78","author":"D Behrens","year":"2018","unstructured":"Behrens, D. et al. Preclinical evaluation of novel treatment strategies in patient-derived xenograft (PDX) models of pancreatic cancer. Cancer Res. 78, 4093\u20134093 (2018).","journal-title":"Cancer Res."},{"key":"69013_CR38","doi-asserted-by":"publisher","first-page":"1113","DOI":"10.1007\/s10555-023-10132-z","volume":"42","author":"L Krau\u00df","year":"2023","unstructured":"Krau\u00df, L., Schneider, C., Hessmann, E., Saur, D. & Schneider, G. Epigenetic control of pancreatic cancer metastasis. Cancer Metastasis Rev. 42, 1113\u20131131 (2023).","journal-title":"Cancer Metastasis Rev."},{"key":"69013_CR39","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-021-27088-9","volume":"13","author":"PF Cheung","year":"2022","unstructured":"Cheung, P. F. et al. Progranulin mediates immune evasion of pancreatic ductal adenocarcinoma through regulation of MHCI expression. Nat. Commun. 13, 156 (2022).","journal-title":"Nat. Commun."},{"key":"69013_CR40","doi-asserted-by":"publisher","first-page":"ra52","DOI":"10.1126\/scisignal.2002918","volume":"5","author":"CL Lee","year":"2012","unstructured":"Lee, C. L. et al. p53 functions in endothelial cells to prevent radiation-induced myocardial injury in mice. Sci. Signal. 5, ra52 (2012).","journal-title":"Sci. Signal."},{"key":"69013_CR41","doi-asserted-by":"publisher","first-page":"1340","DOI":"10.1038\/nm.3646","volume":"20","author":"N Schonhuber","year":"2014","unstructured":"Schonhuber, N. et al. A next-generation dual-recombinase system for time- and host-specific targeting of pancreatic cancer. Nat. Med. 20, 1340\u20131347 (2014).","journal-title":"Nat. Med."},{"key":"69013_CR42","doi-asserted-by":"publisher","first-page":"725","DOI":"10.1038\/s41422-019-0195-y","volume":"29","author":"J Peng","year":"2019","unstructured":"Peng, J. et al. Single-cell RNA-seq highlights intra-tumoral heterogeneity and malignant progression in pancreatic ductal adenocarcinoma. Cell Res. 29, 725\u2013738 (2019).","journal-title":"Cell Res."},{"key":"69013_CR43","doi-asserted-by":"publisher","first-page":"500","DOI":"10.1038\/nm.2344","volume":"17","author":"EA Collisson","year":"2011","unstructured":"Collisson, E. A. et al. Subtypes of pancreatic ductal adenocarcinoma and their differing responses to therapy. Nat. Med. 17, 500\u2013503 (2011).","journal-title":"Nat. Med."},{"key":"69013_CR44","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1038\/nature16965","volume":"531","author":"P Bailey","year":"2016","unstructured":"Bailey, P. et al. Genomic analyses identify molecular subtypes of pancreatic cancer. Nature 531, 47\u201352 (2016).","journal-title":"Nature"},{"key":"69013_CR45","doi-asserted-by":"publisher","DOI":"10.1038\/s41698-020-0114-1","volume":"4","author":"M Allam","year":"2020","unstructured":"Allam, M., Cai, S. & Coskun, A. F. Multiplex bioimaging of single-cell spatial profiles for precision cancer diagnostics and therapeutics. npj Precis. Oncol. 4, 11 (2020).","journal-title":"npj Precis. Oncol."},{"key":"69013_CR46","doi-asserted-by":"publisher","first-page":"813","DOI":"10.1016\/j.trecan.2020.05.003","volume":"6","author":"S Cai","year":"2020","unstructured":"Cai, S., Allam, M. & Coskun, A. F. Multiplex spatial bioimaging for combination therapy design. Trends Cancer 6, 813\u2013818 (2020).","journal-title":"Trends Cancer"},{"key":"69013_CR47","doi-asserted-by":"publisher","first-page":"2378","DOI":"10.1002\/jcp.22574","volume":"226","author":"F Bruzzese","year":"2011","unstructured":"Bruzzese, F. et al. HDAC inhibitor vorinostat enhances the antitumor effect of gefitinib in squamous cell carcinoma of head and neck by modulating ErbB receptor expression and reverting EMT. J. Cell. Physiol. 226, 2378\u20132390 (2011).","journal-title":"J. Cell. Physiol."},{"key":"69013_CR48","doi-asserted-by":"publisher","first-page":"2259","DOI":"10.1158\/0008-5472.CAN-12-2938","volume":"73","author":"SA Gradilone","year":"2013","unstructured":"Gradilone, S. A. et al. HDAC6 inhibition restores ciliary expression and decreases tumor growth. Cancer Res. 73, 2259\u20132270 (2013).","journal-title":"Cancer Res."},{"key":"69013_CR49","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-019-42237-3","volume":"9","author":"T Knox","year":"2019","unstructured":"Knox, T. et al. Selective HDAC6 inhibitors improve anti-PD-1 immune checkpoint blockade therapy by decreasing the anti-inflammatory phenotype of macrophages and down-regulation of immunosuppressive proteins in tumor cells. Sci. Rep. 9, 6136 (2019).","journal-title":"Sci. Rep."},{"key":"69013_CR50","doi-asserted-by":"publisher","first-page":"2850","DOI":"10.4049\/jimmunol.1302778","volume":"193","author":"F Cheng","year":"2014","unstructured":"Cheng, F. et al. A novel role for histone deacetylase 6 in the regulation of the tolerogenic STAT3\/IL-10 pathway in APCs. J. Immunol. 193, 2850\u20132862 (2014).","journal-title":"J. Immunol."},{"key":"69013_CR51","doi-asserted-by":"publisher","first-page":"602","DOI":"10.5966\/sctm.2015-0279","volume":"5","author":"I Kopljar","year":"2016","unstructured":"Kopljar, I. et al. Functional and transcriptional characterization of histone deacetylase inhibitor-mediated cardiac adverse effects in human induced pluripotent stem cell-derived cardiomyocytes. Stem Cells Transl. Med. 5, 602\u2013612 (2016).","journal-title":"Stem Cells Transl. Med."},{"key":"69013_CR52","doi-asserted-by":"publisher","first-page":"235","DOI":"10.1007\/s40264-018-0773-9","volume":"42","author":"RR Shah","year":"2019","unstructured":"Shah, R. R. Safety and tolerability of histone deacetylase (HDAC) inhibitors in oncology. Drug Saf. 42, 235\u2013245 (2019).","journal-title":"Drug Saf."},{"key":"69013_CR53","doi-asserted-by":"publisher","first-page":"3584","DOI":"10.1158\/1078-0432.CCR-21-0238","volume":"27","author":"AM Tsimberidou","year":"2021","unstructured":"Tsimberidou, A. M. et al. Preclinical development and first-in-human study of KA2507, a selective and potent inhibitor of histone deacetylase 6, for patients with refractory solid tumors. Clin. Cancer Res. 27, 3584\u20133594 (2021).","journal-title":"Clin. Cancer Res."},{"key":"69013_CR54","doi-asserted-by":"publisher","first-page":"144","DOI":"10.1038\/s41586-023-06063-y","volume":"618","author":"LA Rojas","year":"2023","unstructured":"Rojas, L. A. et al. Personalized RNA neoantigen vaccines stimulate T cells in pancreatic cancer. Nature 618, 144\u2013150 (2023).","journal-title":"Nature"},{"key":"69013_CR55","doi-asserted-by":"publisher","first-page":"531","DOI":"10.1038\/s41591-023-02760-3","volume":"30","author":"S Pant","year":"2024","unstructured":"Pant, S. et al. Lymph-node-targeted, mKRAS-specific amphiphile vaccine in pancreatic and colorectal cancer: the phase 1 AMPLIFY-201 trial. Nat. Med. 30, 531\u2013542 (2024).","journal-title":"Nat. Med."},{"key":"69013_CR56","doi-asserted-by":"publisher","DOI":"10.1186\/s12967-023-04051-4","volume":"21","author":"K Chen","year":"2023","unstructured":"Chen, K. et al. Immune profiling and prognostic model of pancreatic cancer using quantitative pathology and single-cell RNA sequencing. J. Transl. Med. 21, 210 (2023).","journal-title":"J. Transl. Med."},{"key":"69013_CR57","doi-asserted-by":"publisher","first-page":"1163","DOI":"10.1038\/nm.3952","volume":"21","author":"PK Mazur","year":"2015","unstructured":"Mazur, P. K. et al. Combined inhibition of BET family proteins and histone deacetylases as a potential epigenetics-based therapy for pancreatic ductal adenocarcinoma. Nat. Med. 21, 1163\u20131171 (2015).","journal-title":"Nat. Med."},{"key":"69013_CR58","doi-asserted-by":"publisher","first-page":"937","DOI":"10.1016\/j.immuni.2018.04.005","volume":"48","author":"N Page","year":"2018","unstructured":"Page, N. et al. Expression of the DNA-binding factor TOX promotes the encephalitogenic potential of microbe-induced autoreactive CD8(+) T cells. Immunity 48, 937\u2013950.e938 (2018).","journal-title":"Immunity"},{"key":"69013_CR59","doi-asserted-by":"publisher","DOI":"10.1016\/j.celrep.2025.115541","volume":"44","author":"B Zhao","year":"2025","unstructured":"Zhao, B. et al. PLK1 blockade enhances the anti-tumor effect of MAPK inhibition in pancreatic ductal adenocarcinoma. Cell Rep. 44, 115541 (2025).","journal-title":"Cell Rep."},{"key":"69013_CR60","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-017-16826-z","volume":"7","author":"M Trajkovic-Arsic","year":"2017","unstructured":"Trajkovic-Arsic, M. et al. Apparent diffusion coefficient (ADC) predicts therapy response in pancreatic ductal adenocarcinoma. Sci. Rep. 7, 17038 (2017).","journal-title":"Sci. Rep."},{"key":"69013_CR61","doi-asserted-by":"publisher","first-page":"1461","DOI":"10.1158\/1078-0432.CCR-15-2432","volume":"23","author":"I Heid","year":"2017","unstructured":"Heid, I. et al. Co-clinical assessment of tumor cellularity in pancreatic cancer. Clin. Cancer Res. 23, 1461\u20131470 (2017).","journal-title":"Clin. Cancer Res."},{"key":"69013_CR62","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1038\/s41598-017-17204-5","volume":"7","author":"P Bankhead","year":"2017","unstructured":"Bankhead, P. et al. QuPath: Open source software for digital pathology image analysis. Sci. Rep. 7, 1\u20137 (2017).","journal-title":"Sci. Rep."},{"key":"69013_CR63","doi-asserted-by":"publisher","first-page":"413","DOI":"10.1002\/path.6199","volume":"261","author":"K Aliar","year":"2023","unstructured":"Aliar, K. et al. Hourglass, a rapid analysis framework for heterogeneous bioimaging data, identifies sex disparity in IL-6\/STAT3-associated immune phenotypes in pancreatic cancer.  J. Pathol. 261, 413\u2013426 (2023).","journal-title":"J. Pathol."},{"key":"69013_CR64","doi-asserted-by":"publisher","first-page":"1168","DOI":"10.1038\/ng.3398","volume":"47","author":"RA Moffitt","year":"2015","unstructured":"Moffitt, R. A. et al. Virtual microdissection identifies distinct tumor- and stroma-specific subtypes of pancreatic ductal adenocarcinoma. Nat. Genet. 47, 1168\u20131178 (2015).","journal-title":"Nat. Genet."}],"container-title":["Nature Communications"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41467-026-69013-y","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41467-026-69013-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41467-026-69013-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,2,10]],"date-time":"2026-02-10T16:06:19Z","timestamp":1770739579000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41467-026-69013-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,2,6]]},"references-count":64,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["69013"],"URL":"https:\/\/doi.org\/10.1038\/s41467-026-69013-y","relation":{"has-preprint":[{"id-type":"doi","id":"10.21203\/rs.3.rs-4555029\/v1","asserted-by":"object"}]},"ISSN":["2041-1723"],"issn-type":[{"value":"2041-1723","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,2,6]]},"assertion":[{"value":"9 June 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 January 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 February 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"J.T.S. receives honoraria as a consultant or for continuing medical education presentations from AstraZeneca, Bayer, Boehringer Ingelheim, Bristol-Myers Squibb, Immunocore, MSD Sharp Dohme, Novartis, Roche\/Genentech, and Servier. His institution receives research support from Abalos Therapeutics, AstraZeneca, Boehringer Ingelheim, Bristol-Myers Squibb, Eisbach Bio, Oncolytics Therapeutics and Roche\/Genentech; he holds ownership in FAPI Holding (<3%), all outside the submitted work. The remaining authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"1476"}}